Barclays analyst Gena Wang downgraded Crispr Therapeutics to Equal Weight from Overweight with a price target of $88, down from $99. The company’s Q2 release was “largely incremental,” highlighting the progress of its multiple clinical programs, Wang tells investors in a research note. The analyst is stepping to the sidelines “given some questions on durability” of the allogeneic CAR-T programs and lack of other major data catalysts in the next 12 months.
previous post